Recruiting
Phase 1

Targeted Alpha Therapy

Sponsor:

Modulation Therapeutics, Inc.

Code:

NCT05496686

Conditions

Uveal Melanoma

Metastatic

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

4.7 microCi 225Ac-MTI-201

9.5 microCi of 225Ac-MTI-201

19 microCi of 225Ac-MTI-201

38 microCi of 225Ac-MTI-201

76 microCi of 225Ac-MTI-201

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-26. This information was provided to ClinicalTrials.gov by Modulation Therapeutics, Inc. on 2025-10-30.